AR106325A1 - Agonistas del receptor de glucagón - Google Patents

Agonistas del receptor de glucagón

Info

Publication number
AR106325A1
AR106325A1 ARP160103112A ARP160103112A AR106325A1 AR 106325 A1 AR106325 A1 AR 106325A1 AR P160103112 A ARP160103112 A AR P160103112A AR P160103112 A ARP160103112 A AR P160103112A AR 106325 A1 AR106325 A1 AR 106325A1
Authority
AR
Argentina
Prior art keywords
receptor agonist
glucagon receptor
aib
ethoxy
pharmaceutically acceptable
Prior art date
Application number
ARP160103112A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR106325A1 publication Critical patent/AR106325A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto agonista del receptor de glucagón, caracterizado porque comprende la fórmula: YX¹QGTFX²SDYSKYLDX³KKAX⁴EFVX⁵WLLEX⁶X⁷ en donde X¹ es Aib; X² es T; X³ es Aib; X⁴ es K que se modificó químicamente a través de la conjugación al grupo e-amino de la cadena lateral de K con ([2-(2-amino-etoxi)-etoxi]-acetil)₂-(gGlu)ₐ-CO-(CH₂)ᵇ-CO₂H, en donde a es 1 y b es 18; X⁵ es A; X⁶ es E; y X⁷ está ausente; (SEC ID Nº 12); o una sal del mismo farmacéuticamente aceptable. Reivindicación 5: Un método para tratar el hígado graso, caracterizado porque comprende administrar a un bovino en necesidad del mismo, una cantidad efectiva del agonista del receptor de glucagón de conformidad con cualquiera de las reivindicaciones 1 - 4. Reivindicación 9: Una composición farmacéutica, caracterizada porque comprende el agonista del receptor de glucagón de conformidad con cualquiera de las reivindicaciones 1 - 4 y un portador, diluyente, o excipiente farmacéuticamente aceptable.
ARP160103112A 2015-10-26 2016-10-12 Agonistas del receptor de glucagón AR106325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562246199P 2015-10-26 2015-10-26

Publications (1)

Publication Number Publication Date
AR106325A1 true AR106325A1 (es) 2018-01-03

Family

ID=57200152

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103103A AR106318A1 (es) 2015-10-26 2016-10-11 Agonistas del receptor de glucagón
ARP160103112A AR106325A1 (es) 2015-10-26 2016-10-12 Agonistas del receptor de glucagón

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160103103A AR106318A1 (es) 2015-10-26 2016-10-11 Agonistas del receptor de glucagón

Country Status (25)

Country Link
US (3) US9884093B2 (es)
EP (2) EP3368061B1 (es)
JP (3) JP6354017B2 (es)
KR (1) KR20180053747A (es)
CN (2) CN108348583B (es)
AR (2) AR106318A1 (es)
AU (2) AU2016344433B2 (es)
BR (2) BR112018006920A2 (es)
CA (2) CA3003242C (es)
DK (1) DK3368060T3 (es)
EA (2) EA201890676A1 (es)
ES (2) ES2747908T3 (es)
HR (1) HRP20201353T1 (es)
HU (1) HUE050859T2 (es)
IL (1) IL258092A (es)
LT (1) LT3368060T (es)
MX (2) MX2018005132A (es)
NZ (1) NZ740644A (es)
PL (2) PL3368061T3 (es)
PT (2) PT3368060T (es)
RS (1) RS60567B1 (es)
SI (1) SI3368060T1 (es)
TW (1) TWI622596B (es)
WO (2) WO2017074714A1 (es)
ZA (2) ZA201801756B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MA49459A (fr) * 2017-06-21 2020-04-29 Amgen Inc Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
EP3664833B1 (en) 2017-08-09 2023-05-31 Sanofi Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
EP3684793A1 (en) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
IL280159B1 (en) * 2018-07-23 2024-01-01 Lilly Co Eli Methods of using a GIP/GLP1 co-agonist for diabetes
CN113164559A (zh) * 2018-10-04 2021-07-23 韩美药品株式会社 胰高血糖素和包括胰高血糖素的组合产品的治疗用途
HUE062893T2 (hu) 2018-10-26 2023-12-28 Novo Nordisk As Stabil szemaglutid kompozíciók, és alkalmazásaik
KR20210091230A (ko) * 2018-11-12 2021-07-21 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
US20200268835A1 (en) * 2019-02-27 2020-08-27 Novo Nordisk A/S Compounds For Use in NASH
JP7111917B2 (ja) * 2019-06-28 2022-08-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
US20240020543A1 (en) 2020-10-17 2024-01-18 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004932A (en) 1997-03-06 1999-12-21 Iowa State University Research Foundation, Inc. Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
AU2005203925A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EA020520B1 (ru) * 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
RU2559320C2 (ru) 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
EP2560675A1 (en) * 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
UY33872A (es) 2011-01-20 2012-08-31 Zealand Pharma As Uso de análogos de glucagón acilados
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
WO2013004983A1 (en) * 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
EP2793931A2 (en) * 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
AR091478A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
AR091866A1 (es) * 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
WO2014041375A1 (en) 2012-09-17 2014-03-20 Imperial Innovations Limited Peptide analogues of glucagon and glp1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP6230352B2 (ja) 2013-09-19 2017-11-15 ユニ・チャーム株式会社 動物用排泄物処理材の製造方法および製造装置
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
UA122767C2 (uk) 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US20150150643A1 (en) * 2013-12-02 2015-06-04 The Johns Hopkins University Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation
TW201609800A (zh) * 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
WO2015086733A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098616A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098615A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN106029088A (zh) * 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
WO2016198604A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
BR112017028517A2 (pt) 2015-06-30 2018-08-28 Hanmi Pharm. Co., Ltd. ?composição farmacêutica, vetor, peptídeo, polinucleotídeo e conjugado isolado e composição?
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Also Published As

Publication number Publication date
US20180104312A1 (en) 2018-04-19
SI3368060T1 (sl) 2020-08-31
ZA201802371B (en) 2020-01-29
JP6321299B2 (ja) 2018-05-09
PT3368061T (pt) 2019-10-28
MX2018005132A (es) 2018-06-06
CN108135981B (zh) 2022-04-15
PL3368061T3 (pl) 2020-03-31
JP6354017B2 (ja) 2018-07-11
BR112018006920A2 (pt) 2018-11-06
JP2018504376A (ja) 2018-02-15
EA038330B1 (ru) 2021-08-10
LT3368060T (lt) 2020-08-25
JP7211712B2 (ja) 2023-01-24
PL3368060T3 (pl) 2021-01-11
JP2018508464A (ja) 2018-03-29
ZA201801756B (en) 2019-10-30
ES2747908T3 (es) 2020-03-12
IL258092A (en) 2018-05-31
CN108135981A (zh) 2018-06-08
CA3003242A1 (en) 2017-05-04
US9884093B2 (en) 2018-02-06
NZ740644A (en) 2019-10-25
WO2017074715A1 (en) 2017-05-04
CN108348583A (zh) 2018-07-31
EP3368061A1 (en) 2018-09-05
CA3003242C (en) 2022-08-09
BR112018007225A2 (pt) 2018-10-16
EA201890676A1 (ru) 2019-01-31
CN108348583B (zh) 2022-06-03
EP3368060B1 (en) 2020-06-24
AU2016344433B2 (en) 2018-12-06
JP2018135346A (ja) 2018-08-30
AU2016344433A1 (en) 2018-04-19
US9764004B2 (en) 2017-09-19
EP3368061B1 (en) 2019-08-07
KR20180053747A (ko) 2018-05-23
AU2016344434A1 (en) 2018-06-07
DK3368060T3 (da) 2020-08-24
HUE050859T2 (hu) 2021-01-28
RS60567B1 (sr) 2020-08-31
TWI622596B (zh) 2018-05-01
CA3000538A1 (en) 2017-05-04
ES2809548T3 (es) 2021-03-04
WO2017074714A1 (en) 2017-05-04
US20170112904A1 (en) 2017-04-27
EA201890634A1 (ru) 2018-10-31
AU2016344434B2 (en) 2019-06-06
HRP20201353T1 (hr) 2020-11-27
MX2018005129A (es) 2018-06-06
AR106318A1 (es) 2018-01-03
EP3368060A1 (en) 2018-09-05
TW201726717A (zh) 2017-08-01
US20170114115A1 (en) 2017-04-27
PT3368060T (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
AR106325A1 (es) Agonistas del receptor de glucagón
PH12019501360A1 (en) Glp-1 receptor agonists and uses thereof
PE20220337A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
CL2016002023A1 (es) “compuestos derivados de benzoato-4-(amidoamino)- sustituido con un grupo oxazol dicarboxilico, inhibidores de enteropeptidasa; composición farmacéutica que los comprende; y su uso en el tratamiento de obesidad y diabetes mellitus”. pct
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
DOP2019000201A (es) Compuestos inhibidores del vih
PE20160225A1 (es) Modulacion de la inmunidad tumoral
MX2018004834A (es) Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos.
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
ECSP18026800A (es) Una composición para la acuicultura
CL2019000681A1 (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
SG10201809401XA (en) Liquid protein formulations containing viscosity-lowering agents
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
AR105470A1 (es) Métodos para inducir una respuesta inmune
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
GT201400111A (es) Triazolopiridinas sustituidas
EA201592134A1 (ru) Синергетические композиции
BR112017002183A2 (pt) conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR115877A1 (es) Medios y métodos para el clivaje de la zearalenona
CL2020001173A1 (es) Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas.